Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 2, 2007, Pages 174-178

  Laguno, Montserrat ^a   Larrousse, María ^a   Murillas, Javier ^a   Blanco, José Luis ^a   León, Agathe ^a   Milinkovic, Ana ^a   Loncá, Montserrat ^a   Martinez, Esteban ^a   Sánchez Tapias, José Maria ^a   De Lazzari, Elisa ^a,b   Gatell, Josep Ma ^a   Costa, Josep ^c   Mallolas, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Hospital Clinic Universitari de Barcelona ^*

Author keywords

Chronic hepatitis C virus; Early virologic response; Interferon; Peginterferon 2b; Ribavirin; Sustained virologic response; Treatment

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 33847123630     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802b812d     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Sulkowski M, Thomas D. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
5. Sulkowski MS, Thomas DL, Chaisson RE, et al. Elevated liver enzymes following initiation of antiretroviral therapy. JAMA. 2000;283:2526-2527.
6. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, et al. APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
7. Chung RT, Andersen J, Volberding P, et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
8. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848.
9. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:27-36.
10. Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(Suppl 2):S128-S137.
11. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther. 2004;9:133-138.
12. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005;40:47-52.
13. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis. 2005;41:1806-1809.
14. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS. 2004;18(Suppl):F21-F25.
15. Civeira MR, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol. 1999;31(Suppl 1):237-243.
16. Lee SS, Heathcote EJ, Reddy KR, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 KD). J Hepatol. 2002;37:500-506.
17. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
18. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645-652.
19. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother. 2004;53:15-18.
20. Sherman KE, Shire NJ, Rouster SD, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology. 2005;128:313-327.
21. Torriani F, Ribeiro R, Gilbert T, et al. HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis. 2003;188:1498-1507.
22. Soriano V, Nunez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther. 2004;9:505-509.
23. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36(Suppl 1):145-151.
24. Di Martino V, Thevenot T, Boyer N, et al. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS. 2002;16:441-445.
25. Deleted in proof.
26. Halfon P, Khiri H, Tran A, et al. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response. Eur J Gastroenterol Hepatol. 2003;15:1067-1071.
27. Trimoulet P, de Ledinghen V, Foucher J, et al. Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy. J Med Virol. 2004;72:46-51.
28. Cargnel A, Angeli E, Mainini A, et al. Italian Co-Infection Study (ICOS) Group. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther. 2005;10:309-317.